4 651

Cited 58 times in

Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib

Authors
 Jae Hoon Lee  ;  Jun Yong Park  ;  Do Young Kim  ;  Sang Hoon Ahn  ;  Kwang-Hyub Han  ;  Hyo Jung Seo  ;  Jong Doo Lee  ;  Hye Jin Choi 
Citation
 LIVER INTERNATIONAL, Vol.31(8) : 1144-1149, 2011 
Journal Title
LIVER INTERNATIONAL
ISSN
 1478-3223 
Issue Date
2011
MeSH
Administration, Oral ; Adult ; Aged ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/therapeutic use* ; Benzenesulfonates/administration & dosage ; Benzenesulfonates/therapeutic use* ; Carcinoma, Hepatocellular/diagnostic imaging* ; Carcinoma, Hepatocellular/drug therapy* ; Carcinoma, Hepatocellular/enzymology ; Carcinoma, Hepatocellular/mortality ; Disease-Free Survival ; Female ; Fluorodeoxyglucose F18* ; Humans ; Kaplan-Meier Estimate ; Liver Neoplasms/diagnostic imaging* ; Liver Neoplasms/drug therapy* ; Liver Neoplasms/enzymology ; Liver Neoplasms/mortality ; Male ; Middle Aged ; Niacinamide/analogs & derivatives ; Phenylurea Compounds ; Positron-Emission Tomography* ; Predictive Value of Tests ; Proportional Hazards Models ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/therapeutic use* ; Pyridines/administration & dosage ; Pyridines/therapeutic use* ; Radiopharmaceuticals* ; Republic of Korea ; Retrospective Studies ; Risk Assessment ; Risk Factors ; Survival Rate ; Time Factors ; Treatment Outcome ; Young Adult
Keywords
18F ; FDG PET ; hepatocellular carcinoma ; sorafenib
Abstract
BACKGROUND: Sorafenib (Nexavar) is an orally active multikinase inhibitor that is approved for the treatment of hepatocellular carcinoma (HCC). In this study, we used (18) F-2-fluoro-2-deoxyglucose ((18) F-FDG) with positron emission tomography (PET) to predict the treatment outcome of sorafenib in patients with advanced HCC.

MATERIALS AND METHODS: A total of 29 patients with HCC were included. Baseline (18) F-FDG PET scans were performed a median of 14 days before sorafenib treatment. Sorafenib was administered orally at a dose of 400 mg twice daily. For statistical analysis, the standardized uptake value (SUV) of the most hypermetabolic lesion was obtained and assigned as the SUVmax for each patient.

RESULTS: Among 29 patients, one patient achieved partial remission and 14 patients showed stable disease. The overall survival (OS) and progression free survival (PFS) were 5.1 months [95% confidence interval (CI): 0.0-12.0] and 3.8 months (95% CI: 1.4-6.2). The multivariate analysis of OS showed that four indices, Eastern Cooperative Oncology Group performance status, α-fetoprotein (AFP) concentration, portal vein thrombosis and SUVmax were significant prognostic factors (P=0.030, P=0.024, P=0.020 and P=0.015 respectively). AFP concentration and SUVmax were independent prognostic factors for PFS, too (P=0.003 and P=0.026 respectively). When the patients were divided into two groups: low SUVmax (n=10; <5.00) and high SUVmax (n=19;≥ 5.00), the low SUV group showed significantly longer OS and PFS (P=0.023 and P=0.042 respectively).

CONCLUSION: Our study showed that the degree of FDG uptake is an independent prognostic factor in patients with HCC who undergo sorafenib treatment.
Full Text
http://onlinelibrary.wiley.com/doi/10.1111/j.1478-3231.2011.02541.x/abstract
DOI
10.1111/j.1478-3231.2011.02541.x
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Nuclear Medicine (핵의학교실) > 1. Journal Papers
Yonsei Authors
Kim, Do Young(김도영)
Park, Jun Yong(박준용) ORCID logo https://orcid.org/0000-0001-6324-2224
Ahn, Sang Hoon(안상훈) ORCID logo https://orcid.org/0000-0002-3629-4624
Lee, Jae Hoon(이재훈) ORCID logo https://orcid.org/0000-0002-9898-9886
Lee, Jong Doo(이종두)
Choi, Hye Jin(최혜진) ORCID logo https://orcid.org/0000-0001-5917-1400
Han, Kwang-Hyub(한광협) ORCID logo https://orcid.org/0000-0003-3960-6539
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/94874
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links